GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Current Ratio

Osiris Therapeutics (Osiris Therapeutics) Current Ratio : 3.41 (As of Dec. 2018)


View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Osiris Therapeutics's current ratio for the quarter that ended in Dec. 2018 was 3.41.

Osiris Therapeutics has a current ratio of 3.41. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Osiris Therapeutics's Current Ratio or its related term are showing as below:

OSIR's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.71
* Ranked among companies with meaningful Current Ratio only.

Osiris Therapeutics Current Ratio Historical Data

The historical data trend for Osiris Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Current Ratio Chart

Osiris Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.40 4.81 3.51 2.08 3.41

Osiris Therapeutics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 1.97 2.09 2.19 3.41

Competitive Comparison of Osiris Therapeutics's Current Ratio

For the Biotechnology subindustry, Osiris Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Osiris Therapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Osiris Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Osiris Therapeutics's Current Ratio falls into.



Osiris Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Osiris Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Current Ratio (A: Dec. 2018 )=Total Current Assets (A: Dec. 2018 )/Total Current Liabilities (A: Dec. 2018 )
=70.247/20.592
=3.41

Osiris Therapeutics's Current Ratio for the quarter that ended in Dec. 2018 is calculated as

Current Ratio (Q: Dec. 2018 )=Total Current Assets (Q: Dec. 2018 )/Total Current Liabilities (Q: Dec. 2018 )
=70.247/20.592
=3.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Osiris Therapeutics  (NAS:OSIR) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Osiris Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Osiris Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Osiris Therapeutics (Osiris Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707
Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.
Executives
Reinhart Charles A. Iii director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang officer: Chief Financial Officer ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal officer: Chiel Legal Officer
Linda Palczuk officer: President & CEO 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White director
Thomas J Knapp director 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr officer: Principal Accounting Officer
C Randal Mills director, officer: President & CEO 18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes director
Stephen W Potter officer: Senior Vice President 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill director

Osiris Therapeutics (Osiris Therapeutics) Headlines

From GuruFocus